1. Xie, Peiyi, Yu, Mincheng, Zhang, Bo, Guo, Lei, Li, Hui. 2024. CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma. In Journal of hepatology, 81, 93-107. doi:10.1016/j.jhep.2024.02.009. https://pubmed.ncbi.nlm.nih.gov/38403027/
2. Rump, Patrick, de Leeuw, Nicole, van Essen, Anthonie J, Dijkhuizen, Trijnie, van Ravenswaaij-Arts, Conny M. 2014. Central 22q11.2 deletions. In American journal of medical genetics. Part A, 164A, 2707-23. doi:10.1002/ajmg.a.36711. https://pubmed.ncbi.nlm.nih.gov/25123976/
3. Yu, Jiang, Chen, Wen-Xu, Xie, Wen-Jing, Lin, Dong-Hong, Xu, Jian-Ping. 2021. Silencing of the CrkL gene reverses the doxorubicin resistance of K562/ADR cells through regulating PI3K/Akt/MRP1 signaling. In Journal of clinical laboratory analysis, 35, e23817. doi:10.1002/jcla.23817. https://pubmed.ncbi.nlm.nih.gov/34114685/
4. Wesener, Marie C, Weiler, Sofia M E, Bissinger, Michaela, Schirmacher, Peter, Breuhahn, Kai. 2024. CRKL Enhances YAP Signaling through Binding and JNK/JUN Pathway Activation in Liver Cancer. In International journal of molecular sciences, 25, . doi:10.3390/ijms25158549. https://pubmed.ncbi.nlm.nih.gov/39126118/
5. Natsume, Hiroko, Shinmura, Kazuya, Tao, Hong, Nakamura, Satoki, Sugimura, Haruhiko. 2012. The CRKL gene encoding an adaptor protein is amplified, overexpressed, and a possible therapeutic target in gastric cancer. In Journal of translational medicine, 10, 97. doi:10.1186/1479-5876-10-97. https://pubmed.ncbi.nlm.nih.gov/22591714/